Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Debate Politics Policy

Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing

  • News

Executive Summary

Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.

You may also be interested in...



US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches

Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.

Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Pricing Debate Politics Policy
Latest Headlines

Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'

ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets

Travere Looks Ahead To Phase III In Homocystinuria

Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds

See All
UsernamePublicRestriction

Register

SC143061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By